Saving your money for next purchases
Capmatinib/卡玛替尼
Capmatinib is a highly selective small molecule MET inhibitor. In May 2020, the U.S. FDA approved Tabrecta (Capmatinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METEX 14) mutations. Capmatinib is the first FDA-approved targeted therapy for the MET patient population.
Share:
Products
Our offers
Delivery – when you want and anywhere
A huge selection of best products
Health Classification
Let us work together to protect precious health
